Psoriasis in childhood and adolescence;Psoríase na infância e na adolescência

Anais Brasileiros de Dermatologia

Volumn 84, Issue 1, 2009, Pages 9-22

  Romiti, Ricardo ^a,b   Arnone, Marcelo ^a   Maragno, Luciana ^a   Takahashi, Maria Denise Fonseca ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Adolescent; Child; Clinical features; Epidemiology; Infancy; Psoriasis; Therapeutics

Indexed keywords

CALCIPOTRIOL; COAL TAR; CORTICOSTEROID; CYCLOSPORIN A; DITHRANOL; ETRETIN; INFLIXIMAB; METHOTREXATE; PIMECROLIMUS; RETINOID; TACROLIMUS;

ADOLESCENCE; CHILDHOOD DISEASE; CLINICAL FEATURE; DIAPER DERMATITIS; DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNOBIOLOGY; PHOTOTHERAPY; PROGNOSIS; PSORIASIS; REVIEW;

EID: 66049149014     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/S0365-05962009000100002     Document Type: Review

References (56)

1. Hogan A. Papulosquamous disease. In: Schachner LA, Hansen RC. Pediatric Dermatology. 3rd ed. Edinburgh: Mosby; 2003. p. 643-646
2. Consenso Brasileiro de Psoríase e guias de tratamento. Rio de Janeiro: Sociedade Brasileira de Dermatologia; 2006.
3. Watson W, Cann HM, Farber EM, Nall ML. The genetics of psoriasis. Arch Dermatol. 1972;105:197-207.
4. Burden AD. Management of psoriasis in childhood. Clin Exp Dermatol. 1999;24:341-345
5. Carneiro SCS. Psoríase: mecanismos de doença e implicações terapêuticas [tese]. São Paulo: Faculdade de Medicina da Universidade de São Paulo; 2007.
6. Benoit S, Hamm H. Childhood psoriasis. Clin Dermatol. 2007;25:555-562
7. Ghoreschi K, Weigert C, Röcken M. Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol. 2007;25:574-580
8. Sabat R, Philipp S, Höfflich C, Kreutzer S, Wallace E, Asadullah K, et al. Immunopathogenesis of psoriasis. Exp Dermatol. 2007;16:779-798 (Pubitemid 47377643)
9. Büchau AS, Gallo RL. Innate immunity and antimicrobial defense systems in psoriasis. Clin Dermatol. 2007;25:616-624
10. Cassia FF, Carneiro SC, Marques MTQ, Pontes LF, Filgueira AL, Porto LCS. Psoriasis vulgaris and human leukocyte antigens. J Eur Acad Dermatol Venereol. 2007;21:303-310
11. Valdimarsson H. The genetic basis of psoriasis. Clin Dermatol. 2007;25:563-567
12. Fry L, Baker BS. Triggering psoriasis: the role of infections and medications. Clin Dermatol. 2007;25:606-615
13. Ockenfels HM. Triggermechanismen der Psoriasis. Hautarzt. 2003;54:215-223
14. Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol. 2007;25:535-546
15. Christophers E, Mrowietz U. Psoriasis. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ. Fitzpatrick's - Dermatology in general medicine. 6th ed. New York: McGraw Hill; 2003. p. 407-427
16. Griffiths CEM, Camp RDR, Barker JNWN. Psoriasis. In: Burns T, Breathnach S, Cox N, Griffiths C. Rook's - Textbook of Dermatology. 7th ed. Oxford: Blackwell Publishing, 2004. p. 35.1- 69.
17. Janniger CK, Schwartz RA, Musumeci ML, Tedeschi A, Mirona B, Micali G. Infantile psoriasis. Cutis. 2005;76:173-177
18. Sampaio SAP, Rivitti EA. Dermatologia. 3 ed. São Paulo: Artes Médicas; 2007. p. 231-241
19. Van der Kerkhof P, Schalkwijk J. Psoriasis. In: Bolognia JL, Jorizzo JL, Rapini RP. Dermatology. 2nd ed. New York: Mosby; 2008.
20. Criado PR, Valente NY, Michalany N, Martins JE, Romiti R, Aoki V, et al. An unusual association between scalp psoriasis and alopecia areata: the Renbök phenomenon. Clin Exp Dermatol. 2007;32:320-321
21. Lewkowicz D, Gottlieb AB. Pediatric psoriasis and psoriatic arthritis. Dermatol Ther. 2004;17:364-375
22. Gladman DD, Brockbank J. Psoriatic arthritis. Expert Opin Investig Drugs. 2000;9:1511-1522
23. Kleinert S, Feuchtenberger M, Kneitz C, Tony HP. Psoriatic arthritis: clinical spectrum and diagnostic procedures. Clin Dermatol. 2007;25:519-523
24. Robertson DM, Cabral DA, Malleson PN, Petty RE. Juvenile psoriatic arthritis: followup and evaluation of diagnostic criteria. J Rheumatol. 1996;23:166-170
25. Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F, Muhn CY. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on the therapy. J Am Acad Dermatol. 2007;57:1-27.
26. Naldi L, Gambini D. The clinical spectrum of psoriasis. Clin Dermatol. 2007;25:510-518
27. Griffi CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet. 2007; 370:263-271
28. Murphy M, Kerr P, Grant-Kels JM. The histopathologic spectrum of psoriasis. Clin Dermatol. 2007;25:524-528
29. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445:866-873
30. Menter A, Griffi CEM. Current and future management of psoriasis. Lancet. 2007;370:273-284
31. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826-850
32. Ceovic R, Pasic A, Lipozencic J, Murat-Susic S, Skerlev M, Husar K, et al. Treatment of childhood psoriasis. Acta Dermatovenerol Croat. 2006;14:261-264 (Pubitemid 46154751)
33. Pion IA, Koenig KL, Lim HW. Is dermatologic usage of coal tar carcinogenic? A review of the literature. Dermatol Surg. 1995;21:227-231
34. Cordoro KM. Topical therapy for the management of childhood psoriasis: part I. Skin Therapy Lett. 2008;13:1-3.
35. Choi YJ, Hann SK, Chang SN, Park WH. Infantile psoriasis: successful treatment with topical calcipotriol. Pediatr Dermatol. 2000;17:242-244
36. Darley CR, Cunliffe WJ, Green CM, Hutchinson PE, Klaber MR, Downes N. Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris. Br J Dermatol. 1996;135:390-393
37. Oranje AP, Marcoux D, Svensson A, Hutchinson PE, Klaber MR, Downes N. Topical calcipotriol in childhood psoriasis. J Am Acad Dermatol. 1997;36(2 Pt 1):203-208
38. Travis LB, Silverberg NB. Psoriasis in infancy: therapy with calcipotriene ointment. Cutis. 2001;68:341-344
39. Cordoro KM. Systemic and light therapies for the management of childhood psoriasis: part II. Skin Therapy Lett. 2008;13:1-3.
40. Wolff K. Side-effects of psoralen photochemotherapy (PUVA). Br J Dermatol. 1990;122 Suppl 36:117-125
41. MacDonald A, Burden AD. Psoriasis: advances in pathophysiology and management. Postgrad Med J. 2007;83:690-697 (Pubitemid 350207514)
42. Hersh EM, Carbone PP, Wong VG, Freireich EJ.. Inhibition of primary immune response in man by antimetabolites. Cancer Res. 1965;25:1997-2001.
43. Mitchell MS, Wade ME, DeCenti RC, Bertino JR, Calabresi P. Immune suppressive effects of cytosine arabinoside and methotrexate in man. Ann Intern Med. 1969;70:535-547
44. Gladman DD, Mease PJ, Krueger G, Van der Heidje DM, Antoni C, Helliwell PS, et al. Outcome measures in psoriatic arthritis. J Rheumatol. 2005;32:2262-2269 (Pubitemid 41587879)
45. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851-864
46. Consenso Brasileiro de Psoriase e Guias de Tratamento. Rio de Janeiro: Sociedade Brasileira de Dermatologia; 2006.
47. Chong BF, Wong HK. Immunobiologics in the treatment of psoriasis. Clin Immunol. 2007;123:129-138
48. Smith CH, Anstey AV, Barker JNWN, Burden AD, Chalmers RJ, Chandler D, et al. British Association of Dermatologists: guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol. 2005;153:486-497
49. Goffe B, Cather JC. Etanercept: an overview. J Am Acad Dermatol. 2003; 49(Suppl):S105-11.
50. Gottlieb AB. Etanercept for the treatment of psoriasis and psoriatic arthritis. Dermatol Ther. 2004;17:401-408
51. Tan JK, Alphale A, Malaviya R, Sun Y, Gottlieb AB. Mechanisms of action of etanercept in psoriasis. J Investig Dermatol Symp Proc. 2007;12:38-45.
52. Tyring S, Gottlieb A, Papp K. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trial. Lancet. 2006; 367:29-35.
53. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014-2022 (Pubitemid 37448924)
54. Wu EQ, Feldman SR, Chen L, Kaltenboeck A, Yu AP, Gupta SR, et al. Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population. Curr Med Res Opin. 2008;24:3493-3501
55. Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358:241-251
56. Morris A, Rogers M, Fischer G, Arch B, Williams K. Childhood psoriasis: review of 1262 cases. Pediatr Dermatol. 2001;18:188-198